In sartan-class cardiovascular API manufacturing, tris(dibenzylideneacetone)dipalladium(0) pharma grade is not incorporated into the tablet or capsule matrix; it functions as a homogeneous palladium(0) source during the Suzuki–Miyaura cross-coupling that assembles the biphenyl core. The material is charged at 0.2–0.8 mol% palladium relative to the aryl bromide, with a ligand-to-palladium ratio of 2.0:1–3.0:1 using tri(o-tolyl)phosphine or tri-tert-butylphosphine. The resulting API is released under ICH Q3D Class 2B with an oral permitted daily exposure of 100 µg/day; USP <232>/<233> and Ph. Eur. 5.20 govern elemental impurity analysis, while 21 CFR 211.67 defines equipment cleaning after palladium-contaminated campaigns. In production, catalyst pre-ligation is executed in THF at 25–40 °C under nitrogen until the deep violet solution turns amber; the activated catalyst is charged to a glass-lined reactor with aqueous potassium carbonate and held at 60–75 °C. Phase separation, treatment with activated carbon and trimercaptotriazine-functionalized silica, filtration through a 0.45 µm cartridge, and crystallization from isopropanol/water yield API with residual palladium below 10 ppm for oral dosage. The terminal finished product types are uncoated tablets and hard gelatin capsules containing sartan APIs such as losartan potassium, valsartan, and irbesartan. Dissolved oxygen above 1 ppm and incomplete pre-ligation are the two most common causes of palladium black precipitation and batch-to-batch conversion drift on 1,000 L production lines.

What limits catalyst turnover in Buchwald–Hartwig amination of kinase inhibitor cores?

The C–N coupling of aryl chlorides with primary amines in oncology kinase inhibitor intermediate synthesis uses tris(dibenzylideneacetone)dipalladium(0) pharma grade at 0.5–1.5 mol% palladium; XPhos is applied at a ligand-to-palladium ratio of 1.2:1–2.0:1, and sodium tert-butoxide is charged at 1.4 equiv. Compliance is maintained under ICH Q7 for API manufacturing, with residual palladium controlled by ICH Q3D oral permitted daily exposure of 100 µg/day and verified by USP <233> ICP-MS; REACH regulation EC 1907/2006 applies to solvent and ligand handling. A production-scale 2,000 L Hastelloy C22 reactor is held at 80–100 °C in 1,4-dioxane, with agitation at 70–90 rpm using a pitched-blade turbine; dissolved oxygen is maintained below 1 ppm, and the headspace is purged with three nitrogen/vacuum cycles before liquid charging. The reaction stream is quenched with aqueous citric acid, washed with 5% w/v N-acetylcysteine solution, filtered through diatomaceous earth, solvent-swapped to ethanol, and crystallized. Scavenging is required because free dibenzylideneacetone and residual palladium darken the crude API. Terminal finished product types are hard capsules and film-coated tablets containing kinase inhibitor APIs used in oncology. At catalyst loadings below 0.3 mol%, deactivation by dba dissociation and palladium black precipitation is observed on scale; above 2.0 mol%, scavenger capacity must be increased because crude color and residual palladium burden rise disproportionately.

Heck coupling of antiviral cinnamate intermediates, residual dibenzylideneacetone removal, and injectable API purity

A parenteral antiviral API intermediate is produced by Heck coupling using tris(dibenzylideneacetone)dipalladium(0) pharma grade at 0.5–2.0 mol% palladium, tri(o-tolyl)phosphine at 4:1 ligand-to-palladium, and triethylamine at 1.5–2.0 equiv in DMF at 90–110 °C. Because the terminal product is a lyophilized powder for injection, ICH Q3D parenteral permitted daily exposure of 10 µg/day applies; Ph. Eur. 5.20 and USP <232>/<233> govern palladium control, USP <85> applies to final injectable endotoxin testing, and 21 CFR 211.94 governs container closure systems. The Heck coupling is run under nitrogen; after reaction, the mixture is cooled to 40–50 °C, diluted with ethyl acetate, washed with 5% w/v citric acid and 5% w/v N-acetylcysteine solution, then concentrated through a wiped-film evaporator at 35–40 °C under 0.1 bar vacuum. The concentrate is passed through a trimercaptotriazine-functionalized silica cartridge and recrystallized from acetone/water. Terminal finished product types are sterile lyophilized powder for injection and ready-to-use injectable solution vials. Residual palladium and dba ligand must be controlled below 1 ppm in the parenteral API stream because the permitted daily exposure is only 10 µg/day; activated carbon treatment alone is insufficient for this limit.

Sodium-glucose cotransporter-2 inhibitor APIs intended for film-coated tablets are assembled by Negishi coupling between an aryl bromide and an organozinc reagent. Tris(dibenzylideneacetone)dipalladium(0) pharma grade is used at 0.3–1.0 mol% palladium, with SPhos at 1.5:1 ligand-to-palladium, in THF/NMP 3:1 v/v at 50–70 °C. The organozinc reagent is generated from the corresponding aryl bromide using zinc dust activated with 1,2-dibromoethane and trimethylsilyl chloride. The synthesis train operates under ICH Q7; elemental impurity limits for the oral tablet product follow ICH Q3D oral permitted daily exposure of 100 µg/day, with USP <232>/<233> testing from pilot to commercial batches, and ISO 9001:2015 governs batch record and change control documentation. After coupling, the batch is quenched with saturated ammonium chloride, filtered through Celite, concentrated, and the API is crystallized from ethyl acetate/heptane. A recirculating palladium scavenger cartridge containing thiourea-functionalized resin reduces residual palladium to below 5 ppm before final isolation. Terminal finished product type is film-coated tablets for type 2 diabetes. Published production-scale data for this exact SPhos/THF/NMP configuration is limited; the stated range is based on laboratory optimization and toll-manufacturing batch records.

When Sonogashira alkynylation is held below 30°C to suppress Glaser homocoupling

When Sonogashira alkynylation is run below 30 °C in the preparation of non-nucleoside reverse transcriptase inhibitor antiviral APIs, selectivity for the cross-coupled alkyne over Glaser homocoupling by-product is maintained by slow addition of the terminal alkyne over 2–4 h. Tris(dibenzylideneacetone)dipalladium(0) pharma grade is charged at 0.5–1.5 mol%, copper(I) iodide at 0.5–2.0 mol%, and triphenylphosphine at 2.0–3.0 equiv relative to palladium, in triethylamine/THF 1:1 v/v. The resulting oral antiviral tablets and capsules comply with ICH Q3D Class 2B oral permitted daily exposure of 100 µg/day; USP <232>/<233> and Ph. Eur. 5.20 are used for palladium control, and ICH Q7 is applied to API manufacturing. The reactor is inerted with nitrogen and dissolved oxygen is maintained below 0.5 ppm; the alkyne feed is controlled through a mass-flow-calibrated peristaltic pump to avoid exothermic accumulation. After coupling, the batch is washed with 10% w/v aqueous ammonia to remove copper, then treated with activated carbon and thiourea-functionalized resin. The API is isolated by crystallization from acetonitrile/water. Terminal finished product types are film-coated tablets and granules for oral suspension. Above 35 °C, Glaser dimer formation increases to greater than 2 area% by HPLC and reduces yield.

Parenteral oncology small-molecule APIs containing a hindered heteroaryl chloride are aminated with tris(dibenzylideneacetone)dipalladium(0) pharma grade using BrettPhos or RuPhos at 0.8–2.0 mol% palladium and ligand-to-palladium 1.5:1. Sodium tert-pentoxide is used as base at 1.3–1.5 equiv in cyclopentyl methyl ether at 85–100 °C. Because the terminal product is an injectable solution or lyophilized vial, ICH Q3D parenteral permitted daily exposure of 10 µg/day applies; USP <232>/<233>, Ph. Eur. 5.20, and 21 CFR 211.167 for sterile drug product process validation govern the application. After C–N coupling, the reaction stream is cooled to 45 °C, quenched with citric acid, extracted, and cycled through a recirculating palladium scavenger cartridge containing a thiourea-functionalized resin bed at 2–3 bed volumes/hour. The API is solvent-swapped to ethanol, treated with activated carbon, hot-filtered, and crystallized. Terminal finished product types are single-dose injectable vials and lyophilized powder for reconstitution. BrettPhos-ligated systems are sensitive to oxygen and moisture; residual palladium must be reduced to below 1 ppm in the API before sterile filtration.

Heteroaryl Suzuki–Miyaura coupling for CNS APIs requires stricter dba removal before capsule encapsulation

For a CNS-active API with a heteroaryl–heteroaryl bond, tris(dibenzylideneacetone)dipalladium(0) pharma grade is used at 0.4–1.2 mol% palladium with a di-tert-butylphosphino biphenyl ligand at 1.5:1 ligand-to-palladium, potassium phosphate tribasic 2.0 equiv, in 4:1 toluene/water at 70–85 °C. Compliance follows ICH Q3D oral permitted daily exposure of 100 µg/day and USP <232>/<233>; ICH Q7 applies to the API manufacturing chain, and residual solvent limits are controlled under USP <467>. After coupling, the biphasic mixture is separated, and the organic phase is treated with a thiol-functionalized silica scavenger at 10 wt% relative to crude API, filtered through a 0.2 µm filter, and concentrated. The crude API is recrystallized from ethanol/water. Terminal finished product type is hard gelatin capsules containing the CNS API. Residual palladium above 10 ppm in the API is associated with visible gray discoloration and rejection by the USP <232> drug product requirement; therefore, scavenging is operated to achieve below 5 ppm before encapsulation.